Rheumatoid Arthritis: Update Bulletin #3 - ResearchAndMarkets.com
DUBLIN--(BUSINESS WIRE)--Aug 10, 2018--The “Rheumatoid Arthritis: Update Bulletin #3” newsletter has been added to ResearchAndMarkets.com’s offering.
Business QuestionsHow do KOLs perceive Boehringer Ingelheim’s adalimumab biosimilar, Cyltezo? With three adalimumab biosimilars now approved in Europe, what concerns do prescribers have with regard to multiple biosimilar versions becoming available? How do KOLs view Sandoz’s Rixathon, the second rituximab biosimilar to enter the RA space in Europe? Celltrion is currently developing a subcutaneously administered infliximab biosimilar, but what need is there currently for a subcutaneous version of this product? What concerns might prescribers have regarding Celltrion’s subcutaneous infliximab biosimilar?
For more information about this newsletter visit https://www.researchandmarkets.com/research/23smds/rheumatoid?w=4
View source version on businesswire.com:https://www.businesswire.com/news/home/20180810005178/en/
Laura Wood, Senior Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics:Allergy and Immunology
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY PHARMACEUTICAL
SOURCE: Research and Markets
Copyright Business Wire 2018.
PUB: 08/10/2018 07:43 AM/DISC: 08/10/2018 07:43 AM